Tower Research Capital (TRC)’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-2,544
| Closed | -$7.73K | – | 6017 |
|
|
2024
Q4 | $7.73K | Sell |
2,544
-4,348
| -63% | -$18.9K | ﹤0.01% | 4047 |
|
|
2024
Q3 | $35.8K | Sell |
6,892
-15,088
| -69% | -$75K | ﹤0.01% | 2914 |
|
|
2024
Q2 | $56.5K | Buy |
21,980
+21,274
| +3,013% | +$72.6K | ﹤0.01% | 3007 |
|
|
2024
Q1 | $3.47K | Sell |
706
-6,117
| -90% | -$36.2K | ﹤0.01% | 4858 |
|
|
2023
Q4 | $60K | Buy |
6,823
+5,884
| +627% | +$48.2K | ﹤0.01% | 3013 |
|
|
2023
Q3 | $10.8K | Sell |
939
-2,334
| -71% | -$44.9K | ﹤0.01% | 4077 |
|
|
2023
Q2 | $82.8K | Buy |
3,273
+901
| +38% | +$28.1K | ﹤0.01% | 2175 |
|
|
2023
Q1 | $76K | Sell |
2,372
-711
| -23% | -$22.2K | ﹤0.01% | 2128 |
|
|
2022
Q4 | $57K | Sell |
3,083
-2,131
| -41% | -$48.7K | ﹤0.01% | 2263 |
|
|
2022
Q3 | $141K | Buy |
5,214
+1,831
| +54% | +$37.1K | ﹤0.01% | 2248 |
|
|
2022
Q2 | $47K | Buy |
3,383
+2,423
| +252% | +$37.3K | ﹤0.01% | 2949 |
|
|
2022
Q1 | $19K | Sell |
960
-489
| -34% | -$7.42K | ﹤0.01% | 3598 |
|
|
2021
Q4 | $24K | Sell |
1,449
-987
| -41% | -$16.5K | ﹤0.01% | 3484 |
|
|
2021
Q3 | $68K | Sell |
2,436
-8,671
| -78% | -$247K | ﹤0.01% | 2718 |
|
|
2021
Q2 | $329K | Buy |
11,107
+4,430
| +66% | +$128K | 0.01% | 1516 |
|
|
2021
Q1 | $187K | Buy |
6,677
+2,136
| +47% | +$59.1K | ﹤0.01% | 2069 |
|
|
2020
Q4 | $129K | Sell |
4,541
-8,415
| -65% | -$218K | ﹤0.01% | 2113 |
|
|
2020
Q3 | $326K | Buy |
12,956
+6,432
| +99% | +$169K | ﹤0.01% | 2109 |
|
|
2020
Q2 | $159K | Buy |
+6,524
| New | +$129K | 0.01% | 2013 |
|
|
2020
Q1 | – | Sell |
-2,970
| Closed | -$48K | – | 4072 |
|
|
2019
Q4 | $48K | Buy |
2,970
+1,770
| +148% | +$27.5K | ﹤0.01% | 1371 |
|
|
2019
Q3 | $16K | Buy |
+1,200
| New | +$14.7K | ﹤0.01% | 2640 |
|
|
2018
Q3 | – | Sell |
-246
| Closed | -$7K | – | 4332 |
|
|
2018
Q2 | $7K | Buy |
+246
| New | +$7.39K | ﹤0.01% | 2974 |
|
|
2018
Q1 | – | Sell |
-46
| Closed | -$2K | – | 3949 |
|
|
2017
Q4 | $2K | Sell |
46
-3,104
| -99% | -$89.1K | ﹤0.01% | 3257 |
|
|
2017
Q3 | $87K | Buy |
3,150
+2,550
| +425% | +$61.8K | 0.01% | 1497 |
|
|
2017
Q2 | $16K | Buy |
+600
| New | +$13.4K | ﹤0.01% | 1350 |
|
|
2016
Q4 | – | Sell |
-500
| Closed | -$8K | – | 4498 |
|
|
2016
Q3 | $8K | Buy |
500
+309
| +162% | +$4.49K | ﹤0.01% | 2243 |
|
|
2016
Q2 | $2K | Sell |
191
-647
| -77% | -$11.4K | ﹤0.01% | 3984 |
|
|
2016
Q1 | $15K | Buy |
+838
| New | +$17.1K | ﹤0.01% | 1578 |
|
|
2015
Q3 | – | Sell |
-333
| Closed | -$11K | – | 4912 |
|
|
2015
Q2 | $11K | Sell |
333
-1,977
| -86% | -$50.8K | ﹤0.01% | 2639 |
|
|
2015
Q1 | $48K | Buy |
2,310
+1,069
| +86% | +$18.5K | 0.01% | 1504 |
|
|
2014
Q4 | $21K | Buy |
+1,241
| New | +$21.7K | ﹤0.01% | 1575 |
|
|
2014
Q2 | – | Sell |
-1,400
| Closed | -$44K | – | 4736 |
|
|
2014
Q1 | $44K | Buy |
+1,400
| New | +$43.7K | 0.01% | 1199 |
|
Other funds holding RVNC
Tower Research Capital (TRC)'s RVNC Position: Q1 2025 in Review
Tower Research Capital (TRC) sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 2,544 shares — an estimated $7.73K sold.
Tower Research Capital (TRC) first reported a position in RVNC in Q1 2014 and held it in 32 quarters. The position peaked at $329K in Q2 2021. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Tower Research Capital (TRC) reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 2,544 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $7.73K.
- Tower Research Capital (TRC) first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 32 quarters.
- Tower Research Capital (TRC)'s Revance Therapeutics, Inc. position peaked at $329K in Q2 2021.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2025, filed 15 May 2025.